NRGN and early-onset autosomal dominant Alzheimer disease: However, in a study reported nine years earlier, there were no substantial differences in CSF biomarkers such as neurogranin, t-tau, and p-tau between healthy controls with normal cognitive function and patients with Alzheimer’s disease [260].